Understanding the specifics of a Guardant360 sample report is essential for oncologists, pathologists, and patients navigating advanced cancer care. This document serves as the definitive record of a comprehensive genomic profiling test, detailing the molecular landscape of a patient's tumor. The report translates complex DNA sequencing data into actionable clinical intelligence, guiding therapeutic decisions and offering clarity in complex cases. Access to and comprehension of this report can significantly impact the trajectory of treatment planning.
What is the Guardant360 Test?
The Guardant360 test is a next-generation sequencing (NGS) assay designed to analyze circulating tumor DNA (ctDNA) found in a patient's blood. Unlike traditional tissue biopsies, this liquid biopsy approach provides a less invasive alternative for identifying actionable mutations across a broad spectrum of cancer types. The test examines hundreds of genes known to drive cancer growth and response to therapy, looking for alterations such as point mutations, insertions, deletions, and gene fusions. The resulting sample report provides a detailed map of the tumor's genomic profile.
Key Sections of the Report
A standard Guardant360 sample report is structured to deliver information efficiently, moving from summary to detail. The layout typically begins with a header containing patient and specimen identifiers, followed by a clear summary of the findings. The body of the report is divided into distinct analytical sections, including Variant Summary, Gene-Level Results, and specific Therapeutic Implications. Each section is designed to answer specific questions for the treating physician, ensuring that critical data is not overlooked.
Variant Summary and Tumor Mutational Burden
The Variant Summary table provides a high-level overview, listing all detected alterations with their clinical significance. This section often includes a column indicating whether the variant is targeted by an FDA-approved drug or a clinical trial. The report also calculates the Tumor Mutational Burden (TMB), which measures the number of mutations per megabase of DNA examined. A high TMB can sometimes correlate with responsiveness to immunotherapies, making this a crucial data point for treatment strategy. The summary offers immediate visibility into the most relevant findings.
Interpreting Clinical Actionability
One of the most critical aspects of the Guardant360 report is its classification of variants by clinical actionability. Results are typically categorized as Actionable, Potential Actionable, or Not Actionable. Actionable variants indicate a known, targetable mutation with an associated approved therapy or trial. Potential Actionable variants may require further investigation with additional testing or emerging evidence. This tiered system helps clinicians prioritize treatments and avoid pursuing therapies unlikely to yield benefit, streamlining the decision-making process.
